The 2024 ASCO annual meeting took place from May 31st to June 4th, 2024, in Chicago, Il, USA. This year’s event was primarily an in-person event with virtual broadcasts available. The program at a glance is available here. As has been the case since 2019 we will be assessing the impact of the conference online:
From the view of HCPs:
From the view of pharma companies:
The scope of the analysis is focused on mentions coming worldwide.*
A total of 107K mentions were recorded during the listening period from May 24th, 2024, to June 11th, 2024 (one week before and after the conference).
All mentions came from X (formally known as Twitter).
A total of 12K unique authors were identified.
*#asco24 OR #asco2024 OR (asco NEAR/2 (2024 OR 24))
**#asco24 OR #asco2024 OR (asco NEAR/2 (2024 OR 24))
There was a strong decrease 31,32% increase in overall mentions when compared to ASCO 2023. Amongst the user types classified in this congress tracking, HCPs represent the bulk of the conversations at 74%.
Most liked: This post, published before the conference, is anticipating study results in thoracic cancer with a special mention towards the LAURA trial as well as a detailed algorithm of the current state of treatment in lung cancer.
Most reposts: This post highlighted the ESOPEC clinical trial which showed extended overall survival with the FLOT perioperative chemotherapy regimen in adenocarcinoma of the oesophagus.
Most replied to: The post receiving the most comments were congratulatory messages towards Dr. Manochakian receiving the FASCO designation
This year’s ASCO conference was heavily focused on monoclonal antibody and more particularly daratumumab and antibody drug conjugate studied in the DREAMM-7 and 8 trials.
The IMROZ clinical trial, the most mentioned showing improved PFS and OS with the quad therapy Isa-Vrd vs Vrd alone in transplant ineligible NDMM patients was well received by HCPs.
Topics of discussions (type of treatment)
Volume of mentions
Most mentioned clinical trials
Most mentioned molecules
Top posts from HCPs per engagement
KIM-1 has been highlighted as a novel potential prognostic and predictive biomarker for adjuvant RCC patients. IMmotion-010 is the associated trial. This development generated considerable interest from online HCPs.
CLEAR was the most mentioned trial. It showed that genomic signatures did not help select therapy for RCC patients according to online HCPs.
Topics of discussions (most mentioned biomarkers)
Volume of mentions
Most mentioned cancers
Most mentioned clinical trials
Reactions from HCPs on KIM-1/CLEAR
Comparison year to year
mRCC synditrack : a bi-monthly study focused on the patient and your market needs
mRCC syndicated tracker: eu5 + new in 2023: china
Metastatic Urothelial Carcinoma (mUC): Real World Evidence
mUC bladder syndicated tracker: EU5 + new in 2024 : US & JP
Find out more about Social Media Intelligence just here!